aTyr Pharma to Discuss Efzofitimod Program in Pulmonary Sarcoidosis at FDA Meeting in Mid-April 2026

aTyr Pharma has scheduled a Type C meeting with the FDA to discuss its lead candidate, efzofitimod, for pulmonary sarcoidosis. The meeting, set for mid-April 2026, will review the results of the Phase 3 EFZO-FIT study. While the study did not meet its primary endpoint, clinical benefits were observed across multiple efficacy parameters, and efzofitimod maintained lung function and had a favorable safety profile. aTyr expects to provide an update on the meeting outcome following the receipt of the official meeting minutes.